;PMID: 9879813
;source_file_924.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:43..125] = [t:43..125]
;2)section:[e:129..206] = [t:129..206]
;3)section:[e:210..290] = [t:210..290]
;4)sentence:[e:294..423] = [t:294..423]
;5)sentence:[e:424..521] = [t:424..521]
;6)sentence:[e:522..627] = [t:522..627]
;7)sentence:[e:628..807] = [t:628..807]
;8)sentence:[e:808..930] = [t:808..930]
;9)sentence:[e:931..1219] = [t:931..1219]
;10)sentence:[e:1220..1287] = [t:1220..1287]
;11)sentence:[e:1288..1395] = [t:1288..1395]
;12)sentence:[e:1396..1635] = [t:1396..1635]
;13)sentence:[e:1636..1749] = [t:1636..1749]
;14)section:[e:1753..1797] = [t:1753..1797]

;section 0 Span:0..37
;Arch Toxicol. 1998 Nov;72(11):744-50.
(SEC
  (FRAG (NNP:[0..4] Arch) (NNP:[5..12] Toxicol) (.:[12..13] .)
        (CD:[14..18] 1998) (CC:[19..26] Nov;72-LRB-) (CD:[26..28] 11)
        (-RRB-:[28..29] -RRB-) (CD:[29..33] :744) (::[33..34] -)
        (CD:[34..36] 50) (.:[36..37] .)))

;sentence 1 Span:43..125
;Mechanistic study on liver tumor promoting effects of piperonyl butoxide in 
;rats.
;[97..115]:substance:"piperonyl butoxide"
(SENT
  (NP-HLN
    (NP (JJ:[43..54] Mechanistic) (NN:[55..60] study))
    (PP (IN:[61..63] on)
      (NP
        (NP
          (ADJP
            (NML (NN:[64..69] liver) (NN:[70..75] tumor))
            (VBG:[76..85] promoting))
          (NNS:[86..93] effects))
        (PP (IN:[94..96] of)
          (NP (NN:[97..106] piperonyl) (NN:[107..115] butoxide)))
        (PP-LOC (IN:[116..118] in)
          (NP (NNS:[120..124] rats)))))
    (.:[124..125] .)))

;section 2 Span:129..206
;Okamiya H, Mitsumori K, Onodera H, Ito S, Imazawa T, Yasuhara K, Takahashi
;M.
(SEC
  (FRAG (NNP:[129..136] Okamiya) (NNP:[137..138] H) (,:[138..139] ,)
        (NNP:[140..149] Mitsumori) (NNP:[150..151] K) (,:[151..152] ,)
        (NNP:[153..160] Onodera) (NNP:[161..162] H) (,:[162..163] ,)
        (NNP:[164..167] Ito) (NNP:[168..170] S,) (NNP:[171..178] Imazawa)
        (NNP:[179..180] T) (,:[180..181] ,) (NNP:[182..190] Yasuhara)
        (NNP:[191..192] K) (,:[192..193] ,) (NNP:[194..203] Takahashi)
        (NNP:[204..206] M.)))

;section 3 Span:210..290
;Medicinal Safety Laboratories, Yamanouchi Pharmaceutical Co. Ltd., Tokyo,
;Japan.
(SEC
  (FRAG (NNP:[210..219] Medicinal) (NNP:[220..226] Safety)
        (NNP:[227..239] Laboratories) (,:[239..240] ,)
        (NNP:[241..251] Yamanouchi) (NNP:[252..266] Pharmaceutical)
        (NNP:[267..270] Co.) (NNP:[271..275] Ltd.) (,:[275..276] ,)
        (NNP:[277..282] Tokyo) (,:[282..283] ,) (NNP:[284..289] Japan)
        (.:[289..290] .)))

;sentence 4 Span:294..423
;Piperonyl butoxide, 
;alpha-[2-(2-butoxyethoxy)ethoxy]-4,5-methylenedioxy-2-propyltol uene, is a 
;widely used pesticide-synergist.
;[294..312]:substance:"Piperonyl butoxide"
;[315..383]:substance:"alpha-[2-(2-butoxyethoxy)ethoxy]-4,5-methylenedioxy-2-p
;ropyltol uene"
;[403..412]:substance:"pesticide"
;[413..422]:substance:"synergist"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[294..303] Piperonyl) (NN:[304..312] butoxide))
      (,:[312..313] ,)
      (NP
          (NN:[315..378] alpha--LSB-2--LRB-2-butoxyethoxy-RRB-ethoxy-RSB--4,5-methylenedioxy-2-propyltol)
          (NN:[379..383] uene)))
    (,:[383..384] ,)
    (VP (VBZ:[385..387] is)
      (NP-PRD (DT:[388..389] a)
        (ADJP (RB:[391..397] widely) (VBN:[398..402] used))
        (NN:[403..412] pesticide) (HYPH:[412..413] -) (NN:[413..422] synergist)))
    (.:[422..423] .)))

;sentence 5 Span:424..521
;Recently, results were reported indicating that  piperonyl butoxide is a
;hepatocarcinogen in rat.
;[473..491]:substance:"piperonyl butoxide"
;[497..513]:substance:"hepatocarcinogen"
(SENT
  (S
    (ADVP-TMP (RB:[424..432] Recently))
    (,:[432..433] ,)
    (NP-SBJ-1 (NNS:[434..441] results))
    (VP (VBD:[442..446] were)
      (VP (VBN:[447..455] reported)
        (NP-1 (-NONE-:[455..455] *))
        (S-ADV
          (NP-SBJ-1 (-NONE-:[455..455] *))
          (VP (VBG:[456..466] indicating)
            (SBAR (IN:[467..471] that)
              (S
                (NP-SBJ (NN:[473..482] piperonyl) (NN:[483..491] butoxide))
                (VP (VBZ:[492..494] is)
                  (NP-PRD (DT:[495..496] a) (NN:[497..513] hepatocarcinogen))
                  (PP-LOC (IN:[514..516] in)
                    (NP (NN:[517..520] rat))))))))))
    (.:[520..521] .)))

;sentence 6 Span:522..627
;Since the underlying mechanism  was not elucidated, we examined the effects
;on rat liver cells in detail.
(SENT
  (S
    (SBAR-ADV (IN:[522..527] Since)
      (S
        (NP-SBJ-1 (DT:[528..531] the) (VBG:[532..542] underlying)
                  (NN:[543..552] mechanism))
        (VP (VBD:[554..557] was) (RB:[558..561] not)
          (VP (VBN:[562..572] elucidated)
            (NP-1 (-NONE-:[572..572] *))))))
    (,:[572..573] ,)
    (NP-SBJ (PRP:[574..576] we))
    (VP (VBD:[577..585] examined)
      (NP
        (NP (DT:[586..589] the) (NNS:[590..597] effects))
        (PP (IN:[598..600] on)
          (NP (NN:[601..604] rat) (NN:[605..610] liver) (NNS:[611..616] cells))))
      (PP-MNR (IN:[617..619] in)
        (NP (NN:[620..626] detail))))
    (.:[626..627] .)))

;sentence 7 Span:628..807
;For  this purpose male F344 rats were administered piperonyl butoxide mixed
;in the  diet at concentrations of 0 (negative control), 0.05, 0.2 or 2% for 2
;days, 1,  2, and 4 weeks.
;[679..697]:substance:"piperonyl butoxide"
;[738..739]...[774..775]:quantitative-value:"0"..."%"
;[760..764]...[774..775]:quantitative-value:"0.05"..."%"
;[766..769]...[774..775]:quantitative-value:"0.2"..."%"
;[773..775]:quantitative-value:"2%"
;[780..781]:quantitative-value:"2"
;[782..786]:quantitative-units:"days"
;[788..789]:quantitative-value:"1"
;[792..793]:quantitative-value:"2"
;[799..800]:quantitative-value:"4"
;[801..806]:quantitative-units:"weeks"
(SENT
  (S
    (PP (IN:[628..631] For)
      (NP (DT:[633..637] this) (NN:[638..645] purpose)))
    (NP-SBJ-3 (JJ:[646..650] male) (NN:[651..655] F344) (NNS:[656..660] rats))
    (VP (VBD:[661..665] were)
      (VP (VBN:[666..678] administered)
        (NP-3 (-NONE-:[678..678] *))
        (NP
          (NP (NN:[679..688] piperonyl) (NN:[689..697] butoxide))
          (VP (VBN:[698..703] mixed)
            (NP (-NONE-:[703..703] *))
            (PP (IN:[704..706] in)
              (NP (DT:[707..710] the) (NN:[712..716] diet)))
            (PP (IN:[717..719] at)
              (NP
                (NP (NNS:[720..734] concentrations))
                (PP (IN:[735..737] of)
                  (NP
                    (NP
                      (NP (CD:[738..739] 0)
                        (NML-2 (-NONE-:[739..739] *P*)))
                      (PRN (-LRB-:[740..741] -LRB-)
                        (NP (JJ:[741..749] negative) (NN:[750..757] control))
                        (-RRB-:[757..758] -RRB-)))
                    (,:[758..759] ,)
                    (NP (CD:[760..764] 0.05)
                      (NML-2 (-NONE-:[764..764] *P*)))
                    (,:[764..765] ,)
                    (NP (CD:[766..769] 0.2)
                      (NML-2 (-NONE-:[769..769] *P*)))
                    (CC:[770..772] or)
                    (NP (CD:[773..774] 2)
                      (NML-2 (NN:[774..775] %)))))))
            (PP-TMP (IN:[776..779] for)
              (NP
                (NP (CD:[780..781] 2) (NNS:[782..786] days))
                (,:[786..787] ,)
                (NP (CD:[788..789] 1)
                  (NML-1 (-NONE-:[789..789] *P*)))
                (,:[789..790] ,)
                (NP (CD:[792..793] 2)
                  (NML-1 (-NONE-:[793..793] *P*)))
                (,:[793..794] ,) (CC:[795..798] and)
                (NP (CD:[799..800] 4)
                  (NML-1 (NNS:[801..806] weeks)))))))))
    (.:[806..807] .)))

;sentence 8 Span:808..930
;As a positive control, phenobarbital was administered to rats  for up to 4
;weeks as a 0.1% solution in the drinking water.
;[831..844]:substance:"phenobarbital"
;[881..882]:quantitative-value:"4"
;[883..888]:quantitative-units:"weeks"
;[894..898]:quantitative-value:"0.1%"
;[899..907]:substance:"solution"
;[924..929]:substance:"water"
(SENT
  (S
    (PP-MNR (IN:[808..810] As)
      (NP (DT:[811..812] a) (JJ:[813..821] positive) (NN:[822..829] control)))
    (,:[829..830] ,)
    (NP-SBJ-2 (NN:[831..844] phenobarbital))
    (VP (VBD:[845..848] was)
      (VP (VBN:[849..861] administered)
        (NP-2 (-NONE-:[861..861] *))
        (PP (TO:[862..864] to)
          (NP (NNS:[865..869] rats)))
        (PP-TMP (IN:[871..874] for)
          (NP
            (QP (IN:[875..877] up) (TO:[878..880] to) (CD:[881..882] 4))
            (NNS:[883..888] weeks)))
        (PP-MNR (IN:[889..891] as)
          (NP (DT:[892..893] a)
            (NML (CD:[894..897] 0.1) (NN:[897..898] %))
            (NN:[899..907] solution)))
        (PP-LOC (IN:[908..910] in)
          (NP (DT:[911..914] the) (NN:[915..923] drinking) (NN:[924..929] water)))))
    (.:[929..930] .)))

;sentence 9 Span:931..1219
;Increased liver  weight, centrilobular hepatocellular hypertrophy due to
;increased smooth  endoplasmic reticulum, decreased numbers and areas of
;connexin 32-positive spots  per hepatocyte, and increased cell proliferation
;were observed in rats treated  with 0.2 and 2% piperonyl butoxide.
;[1189..1192]...[1198..1199]:quantitative-value:"0.2"..."%"
;[1197..1199]:quantitative-value:"2%"
;[1200..1218]:substance:"piperonyl butoxide"
(SENT
  (S
    (NP-SBJ-3
      (NP (VBN:[931..940] Increased) (NN:[941..946] liver)
          (NN:[948..954] weight))
      (,:[954..955] ,)
      (NP
        (NP (JJ:[956..969] centrilobular) (JJ:[970..984] hepatocellular)
            (NN:[985..996] hypertrophy))
        (PP (IN:[997..1000] due)
          (PP (TO:[1001..1003] to)
            (NP (VBN:[1004..1013] increased) (JJ:[1014..1020] smooth)
                (JJ:[1022..1033] endoplasmic) (NN:[1034..1043] reticulum)))))
      (,:[1043..1044] ,)
      (NP
        (NP
          (NP
            (ADJP-2 (VBN:[1045..1054] decreased))
            (NNS:[1055..1062] numbers))
          (CC:[1063..1066] and)
          (NP
            (ADJP-2 (-NONE-:[1066..1066] *P*))
            (NNS:[1067..1072] areas)))
        (PP (IN:[1073..1075] of)
          (NP
            (NP
              (ADJP
                (NML (NN:[1076..1084] connexin) (CD:[1085..1087] 32))
                (HYPH:[1087..1088] -) (JJ:[1088..1096] positive))
              (NNS:[1097..1102] spots))
            (PP (IN:[1104..1107] per)
              (NP (NN:[1108..1118] hepatocyte))))))
      (,:[1118..1119] ,) (CC:[1120..1123] and)
      (NP (VBN:[1124..1133] increased) (NN:[1134..1138] cell)
          (NN:[1139..1152] proliferation)))
    (VP (VBD:[1153..1157] were)
      (VP (VBN:[1158..1166] observed)
        (NP-3 (-NONE-:[1166..1166] *))
        (PP-LOC (IN:[1167..1169] in)
          (NP
            (NP (NNS:[1170..1174] rats))
            (VP (VBN:[1175..1182] treated)
              (NP (-NONE-:[1182..1182] *))
              (PP-CLR (IN:[1184..1188] with)
                (NP
                  (NML
                    (NML (CD:[1189..1192] 0.2)
                      (NML-1 (-NONE-:[1192..1192] *P*)))
                    (CC:[1193..1196] and)
                    (NML (CD:[1197..1198] 2)
                      (NML-1 (NN:[1198..1199] %))))
                  (NP (NN:[1200..1209] piperonyl) (NN:[1210..1218] butoxide)))))))))
    (.:[1218..1219] .)))

;sentence 10 Span:1220..1287
;Similar results were obtained for 0.1%  phenobarbital treated rats.
;[1254..1258]:quantitative-value:"0.1%"
;[1260..1273]:substance:"phenobarbital"
(SENT
  (S
    (NP-SBJ-1 (JJ:[1220..1227] Similar) (NNS:[1228..1235] results))
    (VP (VBD:[1236..1240] were)
      (VP (VBN:[1241..1249] obtained)
        (NP-1 (-NONE-:[1249..1249] *))
        (PP (IN:[1250..1253] for)
          (NP
            (ADJP
              (NML
                (NML (CD:[1254..1257] 0.1) (NN:[1257..1258] %))
                (NP (NN:[1260..1273] phenobarbital)))
              (VBN:[1274..1281] treated))
            (NNS:[1282..1286] rats)))))
    (.:[1286..1287] .)))

;sentence 11 Span:1288..1395
;Hepatocellular necrosis suggestive of hepatotoxicity  was also observed in
;the 2% piperonyl butoxide group.
;[1367..1369]:quantitative-value:"2%"
;[1370..1388]:substance:"piperonyl butoxide"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1288..1302] Hepatocellular) (NN:[1303..1311] necrosis))
      (ADJP (JJ:[1312..1322] suggestive)
        (PP (IN:[1323..1325] of)
          (NP (NN:[1326..1340] hepatotoxicity)))))
    (VP (VBD:[1342..1345] was)
      (ADVP (RB:[1346..1350] also))
      (VP (VBN:[1351..1359] observed)
        (NP-1 (-NONE-:[1359..1359] *))
        (PP-LOC (IN:[1360..1362] in)
          (NP (DT:[1363..1366] the)
            (NML
              (NML (CD:[1367..1368] 2) (NN:[1368..1369] %))
               (NN:[1370..1379] piperonyl) (NN:[1380..1388] butoxide))
            (NN:[1389..1394] group)))))
    (.:[1394..1395] .)))

;sentence 12 Span:1396..1635
;These results indicate  that the promoting mechanism of piperonyl butoxide in
;hepatocarcinogenesis is  similar to that of phenobarbital, involving an
;ability to induce CYP isoenzymes  and inhibit gap junctional intercellular
;communication.
;[1452..1470]:substance:"piperonyl butoxide"
;[1518..1531]:substance:"phenobarbital"
;[1564..1578]:cyp450:"CYP isoenzymes"
(SENT
  (S
    (NP-SBJ (DT:[1396..1401] These) (NNS:[1402..1409] results))
    (VP (VBP:[1410..1418] indicate)
      (SBAR (IN:[1420..1424] that)
        (S
          (NP-SBJ
            (NP (DT:[1425..1428] the) (VBG:[1429..1438] promoting)
                (NN:[1439..1448] mechanism))
            (PP (IN:[1449..1451] of)
              (NP (NN:[1452..1461] piperonyl) (NN:[1462..1470] butoxide)))
            (PP (IN:[1471..1473] in)
              (NP (NN:[1474..1494] hepatocarcinogenesis))))
          (VP (VBZ:[1495..1497] is)
            (ADJP-PRD (JJ:[1499..1506] similar)
              (PP (TO:[1507..1509] to)
                (NP
                  (NP (DT:[1510..1514] that))
                  (PP (IN:[1515..1517] of)
                    (NP (NN:[1518..1531] phenobarbital))))))
            (,:[1531..1532] ,)
            (S-ADV
              (NP-SBJ (-NONE-:[1532..1532] *))
              (VP (VBG:[1533..1542] involving)
                (NP (DT:[1543..1545] an) (NN:[1546..1553] ability)
                  (S
                    (NP-SBJ (-NONE-:[1553..1553] *))
                    (VP (TO:[1554..1556] to)
                      (VP
                        (VP (VB:[1557..1563] induce)
                          (NP (NN:[1564..1567] CYP)
                              (NNS:[1568..1578] isoenzymes)))
                        (CC:[1580..1583] and)
                        (VP (VB:[1584..1591] inhibit)
                          (NP
                            (ADJP (NN:[1592..1595] gap)
                                  (JJ:[1596..1606] junctional))
                            (JJ:[1607..1620] intercellular)
                             (NN:[1621..1634] communication)))))))))))))
    (.:[1634..1635] .)))

;sentence 13 Span:1636..1749
;In addition, increased  cell proliferation following hepatocellular necrosis
;may also play a role at  high doses.
(SENT
  (S
    (PP (IN:[1636..1638] In)
      (NP (NN:[1639..1647] addition)))
    (,:[1647..1648] ,)
    (NP-SBJ
      (NP (VBN:[1649..1658] increased) (NN:[1660..1664] cell)
          (NN:[1665..1678] proliferation))
      (PP (VBG:[1679..1688] following)
        (NP (JJ:[1689..1703] hepatocellular) (NN:[1704..1712] necrosis))))
    (VP (MD:[1713..1716] may)
      (ADVP (RB:[1717..1721] also))
      (VP (VB:[1722..1726] play)
        (NP (DT:[1727..1728] a) (NN:[1729..1733] role))
        (PP (IN:[1734..1736] at)
          (NP (JJ:[1738..1742] high) (NNS:[1743..1748] doses)))))
    (.:[1748..1749] .)))

;section 14 Span:1753..1797
;PMID: 9879813 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1753..1757] PMID) (::[1757..1758] :) (CD:[1759..1766] 9879813)
        (NN:[1767..1768] -LSB-) (NNP:[1768..1774] PubMed) (::[1775..1776] -)
        (NN:[1777..1784] indexed) (IN:[1785..1788] for)
        (NNP:[1789..1797] MEDLINE-RSB-)))
